Page 8 - Pharmaceutical

Drug trials on human tissues, cells made in labs soon; new rules in offing

Pre-clinical trials of new drugs could soon be done on human tissues and cells developed in laboratories and not just on animals as the Union Health Ministry is working on bringing in amendments to the New Drugs and Clinical Trials Rules, 2019. A recent draft notification to amend the rules stated that alternative technology platforms such as human organ on chips, micro-physiological systems and other in vitro or cell-based assays can be used prior to and in conjunction with animal testing to establish the safety and efficacy of new drugs before human clinical trials. Pre-clinical tests are important for establishing the safety and efficacy of investigational drugs. In September, the US Congress approved a landmark FDA Modernization Bill that allows a pharmaceutical drug developer to use alternative methods -- including cell-based assays, organ on chips, micro-physiological systems and other human biology-based test methods -- for establishing the safety and effectiveness of new or

Pharma logs 17% growth in Nov; anti-infective therapy drives market demand

Key antibiotic brands like Augmentin (GSK) and Clavam (Alkem) clocked 25 per cent and 29 percent growth, respectively, in November, the data showed

Innovator drugs maintain market hold even after patent expiry, shows data

Merck's anti-diabetic molecule sitagliptin retains 81% market share in value terms

Viatris deal gives Biocon Biologics entry in 100 countries: Shreehas Tambe

In a Q&A, the recently named MD & CEO of Biocon Biologics dwells on the scope for an IPO or stake sale to PE investors to retire the debt taken to fund the acquisition

Gland Pharma to acquire French firm Cenexi Group for Rs 1,000 crore

Will fund transaction from internal accruals

Bharat Bio looks for partners to manufacture, distribute iNCOVACC globally

Its local production ramp-up remains unhurried as demand for boosters reduces

China-Plus-One strategy: Indian API firms start to reap benefits

Rising Chinese labour costs, geopolitics, pandemic-stricken uncertainties have forced global players to derisk

Akums chalks out expansion plan as it eyes Rs 10,000 cr turnover by 2028

Leading contract manufacturing drug firm Akums Drugs & Pharmaceuticals plans to expand its presence globally and enhance product range as it looks to more than double its turnover to Rs 10,000 crore by 2028, as per the company's Joint Managing Director Sandeep Jain. The company, which produces around 12 per cent of all the medicines consumed in the country from its 15 manufacturing facilities, has a topline of about Rs 4,000 crore currently. In an interaction with PTI, Jain said the company would be able to achieve its stated financial targets even if it continues to grow at the same pace it has been doing over the last few years. He noted that the demand for pharmaceutical products is going to stay robust in the domestic market, with some estimates pointing towards the market doubling by 2030. "We expect to touch a turnover of Rs 10,000 crore in the next five years (2028)from the current level of Rs 4,000 crore. Our plan is to keep growing by at least 12-15 (CAGR)," Jain ...

World in turmoil, domestic pharma firms target India for healthy growth

Share of India revenue in home-grown firms' consolidated turnover rising over the years

Top 300 drug brands to now have QR codes on label for ensuring authenticity

Govt finalises the draft notification issued in June

After the Gambia, Nigeria, Liberia issue alerts over Maiden Pharma's syrups

Nigeria has reportedly circulated the alert across all professional bodies, health care providers and supply chain associates

New Jersey-based Amneal Pharma starts mfg operations for Indian market

The firm already has manufacturing units in four Indian cities, all of which are focused on the export market

Can Roche stay ahead of the competition in the next 125 years?

Pharma giant Roche believes, its ability to reinvent itself through innovation was behind its success. Business Standard's Sohini Das and Nivedita Mookerji spoke to the members of its founding family

Govt working on PLI schemes for more products to boost manufacturing: Goyal

The government had rolled out PLI schemes for 15 key sectors, including technology, textile, automobile, pharmaceutical drugs, speciality steel, electronics, among others

Currency internationalisation: India pushes for rupee trade with Cuba

In July, the RBI had unveiled a mechanism to settle international transactions in rupee to promote the growth of global trade, with emphasis on exports from India

Pharma body clears Micro Labs of charges of spending Rs 1000 cr on freebies

Indian Pharmaceutical Alliance ethics committee submits report to NPPA

Largest Ibuprofen API maker eyes double revenue in next four years

As part of de-risking their business, they have started reducing the share of ibuprofen in their overall turnover, and add more popular products to the portfolio

DOLO-650 makers distributed freebies worth Rs 1,000 cr to doctors: FMRAI

The petitioner, while seeking statutory backing to the Uniform Code of Pharmaceutical Marketing Practices (UCPMP), said that corruption in pharma marketing practices is yet unregulated in India

Specialty drugs may push Sun Pharma's US biz beyond $2 bn by 2025

The share of specialty medicines in overall pharmaceutical spending has been consistently increasing over the past decade, from 22 per cent in 2011 to 39 per cent in 2021

Senate Democrats approve big Biden deal worth $740 bn; House to vote next

Democrats pushed their election-year economic package to Senate passage, a hard-fought compromise less ambitious than Biden's original domestic vision but one that still meets deep-rooted party goals